Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and δ9-tetrahydrocannabinol in rat plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 114, Issue , 2015, Pages 145-151

  Zgair, Atheer ^a,b   Wong, Jonathan C M ^a   Sabri, Akmal ^a   Fischer, Peter M ^a   Barrett, David A ^a   Constantinescu, Cris S ^a   Gershkovich, Pavel ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF ANBAR   (Iraq)

Author keywords

Cannabidiol; HPLC UV; Pharmacokinetics; Rat plasma; 9 Tetrahydrocannabinol

Indexed keywords

ACETONITRILE; CANNABIDIOL; CHLORPHENOTANE; DRONABINOL; HEXANE; PROTEIN; RIFAMPICIN; SOLVENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; ELUTION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MEASUREMENT ACCURACY; NONHUMAN; PLASMA; PRECIPITATION; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; STANDARD; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; ANIMAL; BLOOD; CHEMISTRY; DRUG CONTAMINATION; GREEN CHEMISTRY; METABOLISM; PH; PROCEDURES; SENSITIVITY AND SPECIFICITY; SUPERCRITICAL FLUID CHROMATOGRAPHY; TEMPERATURE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; CANNABIDIOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRONABINOL; DRUG CONTAMINATION; GREEN CHEMISTRY TECHNOLOGY; HYDROGEN-ION CONCENTRATION; PLASMA; RATS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET; TEMPERATURE;

EID: 84930944864     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.05.019     Document Type: Article

References (53)

1. Zuardi A.W. History of cannabis as a medicine: a review. Rev. Bras. Psiquiatr. 2006, 28:153-157.
2. Russo E. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J. Cannabis Ther. 2001, 1:21-92.
3. Kalant H. Medicinal use of cannabis: history and current status. Pain Res. Manag. 2001, 6:80-94.
4. Pertwee R. Handbook of Cannabis 2014, Oxford University Press.
5. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006, 147:S163-S171.
6. Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G., Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014, 82:1556-1563.
7. Mackie K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 2008, 20:10-14.
8. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs innovative therapeutics or designer drugs of abuse?. Mol. Interv. 2011, 11:36-51.
9. Armentano P. Emerging Clinical Applications For Cannabis and Cannabinoids: A Review of the Recent Scientific Literature 2014, The National Organization for the Reform of Marijuana Laws, Washington, DC.
10. Sznitman S.R., Zolotov Y. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int. J. Drug Policy 2015, 26:20-29.
11. Wright S., Guy G. Licensed Cannabis-Based Medicines: Benefits and Risks, Handbook of Cannabis 2014, 373.
12. Collins T.R. Special report what neurologists are doing about medical marijuana. Neurol. Today 2014, 14:1-28.
13. Zhornitsky S., Potvin S. Cannabidiol in humans - the quest for therapeutic targets. Pharmaceuticals (Basel) 2012, 5:529-552.
14. 9 tetrahydrocannabinol and cannabidiol. Euphytica 2004, 140:73-82.
15. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 2006, 105:1-25.
16. Tanasescu R., Constantinescu C.S. Cannabinoids and the immune system: an overview. Immunobiology 2010, 215:588-597.
17. Lyman W.D., Sonett J.R., Brosnan C.F., Elkin R., Bornstein M.B. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1989, 23:73-81.
18. El-Remessy A.B., Khalil I.E., Matragoon S., Abou-Mohamed G., Tsai N.J., Roon P., Caldwell R.B., Caldwell R.W., Green K., Liou G.I. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-d-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 2003, 163:1997-2008.
19. Jamontt J.M., Molleman A., Pertwee R.G., Parsons M.E. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br. J. Pharmacol. 2010, 160:712-723.
20. Izquierdo I., Tannhauser M. Letter: the effect of cannabidiol on maximal electroshock seizures in rats. J. Pharm. Pharmacol. 1973, 25:916-917.
21. Chiu P., Olsen D.M., Borys H.K., Karler R., Turkanis S.A. The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 1979, 20:365-375.
22. Hill A.J., Weston S.E., Jones N.A., Smith I., Bevan S.A., Williamson E.M., Stephens G.J., Williams C.M., Whalley B.J. Delta(9)-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 2010, 51:1522-1532.
23. Jones N.A., Glyn S.E., Akiyama S., Hill T.D., Hill A.J., Weston S.E., Burnett M.D., Yamasaki Y., Stephens G.J., Whalley B.J., Williams C.M. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21:344-352.
24. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332:569-577.
25. Costa B., Colleoni M., Conti S., Parolaro D., Franke C., Trovato A.E., Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:294-299.
26. Guimaraes F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990, 100:558-559.
27. Almeida V., Levin R., Peres F.F., Niigaki S.T., Calzavara M.B., Zuardi A.W., Hallak J.E., Crippa J.A., Abilio V.C. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 41:30-35.
28. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991, 104:260-264.
29. Klausner H.A., Dingell J.V. The metabolism and excretion of delta 9-tetrahydrocannabinol in the rat. Life Sci. Physiol. Pharmacol. 1971, 10(Pt. 1):49-59.
30. Siemens A.J., Walczak D., Buckley F.E. Characterization of blood disappearance and tissue distribution of [3H]cannabidiol. Biochem. Pharmacol. 1980, 29:462-464.
31. Alozie S.O., Martin B.R., Harris L.S., Dewey W.L. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol. Biochem. Behav. 1980, 12:217-221.
32. Huestis M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007, 4:1770-1804.
33. 9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. J. Chromatogr. B 2004, 803:243-248.
34. Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Platt B., Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012, 219:859-873.
35. Grebe S.K., Singh R.J. LC-MS/MS in the clinical laboratory - where to from here?. Clin. Biochem. Rev. 2011, 32:5.
36. Tsuji M., Mori Y., Kanda H., Ito T., Hidaka T., Kakamu T., Kumagai T., Hayakawa T., Osaki Y., Fukushima T. Development of Simple HPLC/UV With a Column-Switching Method for the Determination of Nicotine and Cotinine in Hair Samples 2013.
37. Ohlsson A., Lindgren J.E., Andersson S., Agurell S., Gillespie H., Hollister L.E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed. Environ. Mass Spectrom. 1986, 13:77-83.
38. Abbara C., Galy R., Benyamina A., Reynaud M., Bonhomme-Faivre L. Development and validation of a method for the quantitation of Delta9 tetrahydrocannabinol in human plasma by high performance liquid chromatography after solid-phase extraction. J. Pharm. Biomed. Anal. 2006, 41:1011-1016.
39. Thompson L.K., Cone E.J. Determination of delta 9-tetrahydrocannabinol in human blood and saliva by high-performance liquid chromatography with amperometric detection. J. Chromatogr. 1987, 421:91-97.
40. Consroe P., Kennedy K., Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol. Biochem. Behav. 1991, 40:517-522.
41. Kintz P., Cirimele V. Testing human blood for cannabis by GC-MS. Biomed. Chromatogr. 1997, 11:371-373.
42. Gustafson R.A., Moolchan E.T., Barnes A., Levine B., Huestis M.A. Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 798:145-154.
43. Karschner E.L., Barnes A.J., Lowe R.H., Scheidweiler K.B., Huestis M.A. Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal. Bioanal. Chem. 2010, 397:603-611.
44. Grauwiler S.B., Scholer A., Drewe J. Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 850:515-522.
45. U.S.Department of Health and Human Services Guidance for Industry, Bioanalytical Method Validation 2001, http://www.fda.%20gov/cder/guidance/index.htm.
46. Gershkovich P., Ibrahim F., Sivak O., Darlington J.W., Wasan K.M. A simple and sensitive method for determination of vitamins D3 and K1 in rat plasma: application for an in vivo pharmacokinetic study. Drug Dev. Ind. Pharm. 2014, 40:338-344.
47. Gershkovich P., Qadri B., Yacovan A., Amselem S., Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur. J. Pharm. Sci. 2007, 31:298-305.
48. Polson C., Sarkar P., Incledon B., Raguvaran V., Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2003, 785:263-275.
49. Souverain S., Rudaz S., Veuthey J.L. Protein precipitation for the analysis of a drug cocktail in plasma by LC-ESI-MS. J. Pharm. Biomed. Anal. 2004, 35:913-920.
50. Casas M.E., Hansen M., Krogh K.A., Styrishave B., Björklund E. Analytical sample preparation strategies for the determination of antimalarial drugs in human whole blood, plasma and urine. J. Chromatogr. B 2014, 962:109-131.
51. Kole P.L., Venkatesh G., Kotecha J., Sheshala R. Recent advances in sample preparation techniques for effective bioanalytical methods. Biomed. Chromatogr. 2011, 25:199-217.
52. Valiveti S., Stinchcomb A.L. Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 803:243-248.
53. Valiveti S., Agu R.U., Hammell D.C., Paudel K.S., Earles D.C., Wermeling D.P., Stinchcomb A.L. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. Eur. J. Pharm. Biopharm. 2007, 65:247-252.